PGT-A

PGT-A involves biopsying embryos at the blastocyst stage and testing them for chromosomal abnormalities, so that only embryos found to be chromosomally typical are put forward for transfer. The controversy is genuine: it can raise implantation rates per transfer, but whether it improves the overall chance of a live birth across a full course of treatment is still debated. The HFEA rates fertility add-ons like this one on its public add-ons list, which is worth checking directly, since benefit depends heavily on individual circumstances such as age and reproductive history.

PGT-A typically adds around £1,500 to £3,000 on top of a standard IVF cycle, though the exact figure depends on how many embryos are tested and the clinic's own pricing. It's worth asking whether that quote covers every embryo you produce or a set number, and what happens cost-wise if none survive to the blastocyst stage needed for biopsy. As with any HFEA-rated add-on, ask your clinic for a full breakdown rather than relying on a headline figure, and check the HFEA add-ons list for its current rating before comparing quotes.

PGT-A tends to come up in conversation for people with recurrent miscarriage, a known chromosomal condition, advanced maternal age, or repeated IVF failure. It isn't a routine part of every IVF cycle, and the HFEA's add-on rating reflects that its benefit varies a lot by individual circumstance rather than applying evenly across the board. If it's been raised with you, it's worth asking your consultant why they think it fits your particular history, and checking the current HFEA add-ons list for its independent rating before deciding.

A few things are worth knowing before deciding. Not every embryo survives in the lab long enough to reach the blastocyst stage needed for biopsy, so some people end up with fewer embryos to test than they started with, and the biopsy itself carries a small handling risk. There's also genuine debate over whether PGT-A improves overall live-birth chances even though it can raise implantation rates per transfer. The HFEA add-ons list sets out the current evidence rating and is worth reading closely before you commit to it.

Yes, PGT-A is available alongside standard IVF at a number of UK clinics, around 52 according to current directory listings. In practice, embryos are grown to the blastocyst stage, a small number of cells are biopsied and sent for genetic analysis, and only embryos reported as chromosomally typical are considered for transfer. Because not every embryo reaches that stage, some cycles end with fewer options than expected. It's worth asking a prospective clinic how they handle results and timelines, and checking the HFEA add-ons list for its independent view on this specific add-on.